Infliximab response study by a gene type in Crohn’s disease
Treatments studied
Part of Digestive system clinical trials.
This trial looks at whether a specific genetic marker (HLADQA1*05) is linked to how well infliximab works in adults with Crohn’s disease. It may help doctors better predict who benefits from infliximab in people with Crohn’s.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) with a diagnosis of Crohn’s disease
- Your current Crohn’s symptom score (CDAI) is between 220 and 450
- You have a reason to use infliximab (IFX) based on the study’s treatment guidelines
- You and/or your family can understand the study and agree to sign consent
- You have not used infliximab or other anti-TNF biologic medicines before
- You do not have the specific excluded gene types: NUDT15 CT or TT
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how infliximab (a medicine that calms immune inflammation) moves through the body in children with Crohn’s disease. It mainly helps doctors understand dosing and drug levels, especially when treatment is newly starting.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
Hear when a new Infliximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.